ASX ANNOUNCEMENT 30 October 2026 QUARTERLY ACTIVITIES REPORT FOR Q1 FY2027 ASX ANNOUNCEMENT Key Highlights Transformative US$33M Fundraising into Zelira’s HOPE® 1 SPV ® • Zelira’s HOPE 1 SPV signed definitive agreements to raise US$32,981,075 (before costs), announced 16 January ® • On a...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- Long Term Suspended Entities
- Suspension from Official Quotation - Annual Listing Fees
- Suspension from Quotation
- Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
- Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics